Related Experiment Video
Updated: Jan 30, 2026

Author Spotlight: Optimizing Apoplast Protein Extraction for Efficient Recovery of Recombinant Proteins from Plant Cells
Published on: July 5, 2024
Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD
Roman Fadeev1,2, Alexey Chekanov3,4, Marina Solovieva5
1Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, Moscow Region 142290, Russia. fadeevrs@gmail.com.
Abstract:
One of the main problems in oncology is the development of drugs that cause the death of cancer cells without damaging normal cells. Another key problem to be solved is to suppress the drug resistance of cancer cells. The third important issue is to provide effective penetration of drug molecules to cancer cells. TRAIL (TNFα-related apoptosis inducing ligand)/Apo2L is a highly selective anticancer agent. However, the recombinant TRAIL protein having high efficiency against cancer cells in vitro was not effective in clinical trials. Recently we have discovered an acquisition of TRAIL resistance by cancer cells in confluent cultures, which is apparently a manifestation of the general phenomenon of multicellular resistance. The aim of this study was to evaluate whether the anticancer effect of the recombinant protein TRAIL in vivo can be improved by the suppression of multicellular TRAIL-resistance using sorafenib and a tumor-penetrating peptide iRGD, c(CRGDKGPDC). The results testified a great increase in the resistance of human fibrosarcoma HT-1080 cells to izTRAIL both in confluent cultures and in spheroids. Sorafenib administered at nontoxic concentration effectively suppressed confluent- or spheroid-mediated TRAIL-resistance of HT-1080 cells in vitro. Sorafenib combined with iRGD significantly improved the anticancer effect of the recombinant protein izTRAIL in HT-1080 human fibrosarcoma grafts in BALB/c nude mice. Consistent with this finding, multicellular TRAIL-resistance may be a reason of inefficacy of izTRAIL alone in vivo. The anticancer effect of the recombinant protein izTRAIL in vivo may be improved in combination with sorafenib, an inhibitor of multicellular TRAIL resistance and iRGD, the tumor-penetrating peptide.
Insights
Multicellular resistance hinders cancer drug effectiveness. Combining TRAIL (TNFα-related apoptosis inducing ligand) with sorafenib and iRGD peptide overcomes this resistance, significantly improving anticancer effects in vivo.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Developing cancer drugs that selectively kill tumor cells without harming normal cells is a major challenge.
- Overcoming cancer cell drug resistance and ensuring effective drug delivery to tumors are critical unmet needs in oncology.
- Recombinant TRAIL (TNFα-related apoptosis inducing ligand) protein shows promise as a selective anticancer agent, but its in vivo efficacy is limited by multicellular resistance.
Purpose of the Study:
- To investigate if combining the recombinant TRAIL protein with sorafenib and the tumor-penetrating peptide iRGD can overcome multicellular TRAIL resistance and enhance anticancer effects in vivo.
- To evaluate the efficacy of sorafenib in suppressing multicellular TRAIL resistance in cancer cells.
- To assess the combined effect of sorafenib and iRGD on the therapeutic potential of TRAIL against human fibrosarcoma xenografts.
Main Methods:
- Assessing the development of TRAIL resistance in human fibrosarcoma HT-1080 cells in confluent cultures and spheroids.
- Evaluating the ability of sorafenib at non-toxic concentrations to inhibit multicellular TRAIL resistance in vitro.
- Testing the combined efficacy of recombinant TRAIL (izTRAIL) with sorafenib and iRGD in a mouse model of human fibrosarcoma HT-1080 grafts.
Main Results:
- Human fibrosarcoma HT-1080 cells exhibited increased resistance to izTRAIL in confluent cultures and spheroids.
- Sorafenib effectively suppressed TRAIL resistance mediated by confluent or spheroid cancer cells in vitro.
- The combination of sorafenib and iRGD significantly enhanced the anticancer effect of izTRAIL in HT-1080 fibrosarcoma tumors in mice.
Conclusions:
- Multicellular resistance is a key factor contributing to the inefficacy of TRAIL alone in vivo.
- Sorafenib can effectively inhibit multicellular TRAIL resistance.
- Combining TRAIL with sorafenib and the tumor-penetrating peptide iRGD represents a promising strategy to improve the in vivo anticancer efficacy of TRAIL.
More Related Videos
14:58Identification of Protein Complexes in Escherichia coli using Sequential Peptide Affinity Purification in Combination with Tandem Mass Spectrometry
Published on: November 12, 2012
07:35Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli
Published on: June 9, 2014
Related Concept Videos
Recombinant DNA
Peptide Bonds
Homologous Recombination
Viral Recombination
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Overview of Transposition and Recombination